Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
Adolescent
Adult
Cord Blood Stem Cell Transplantation
/ adverse effects
Disease-Free Survival
Female
Fetal Blood
/ cytology
Graft Survival
Graft vs Host Disease
/ etiology
Hematologic Neoplasms
/ blood
Humans
Male
Middle Aged
Neutrophils
/ cytology
Niacinamide
/ pharmacology
Transplantation Conditioning
/ methods
Young Adult
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
10 02 2019
10 02 2019
Historique:
pubmed:
14
12
2018
medline:
18
12
2019
entrez:
8
12
2018
Statut:
ppublish
Résumé
Increasing the number of hematopoietic stem and progenitor cells within an umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB transplantation. In this study, we assessed the safety and efficacy of a UCB graft that was expanded ex vivo in the presence of nicotinamide and transplanted after myeloablative conditioning as a stand-alone hematopoietic stem-cell graft. Thirty-six patients with hematologic malignancies underwent transplantation at 11 sites. The cumulative incidence of neutrophil engraftment at day 42 was 94%. Two patients experienced secondary graft failure attributable to viral infections. Hematopoietic recovery was compared with that observed in recipients of standard UCB transplantation as reported to the Center for International Blood and Marrow Transplant Research (n = 146). The median time to neutrophil recovery was 11.5 days (95% CI, 9 to 14 days) for recipients of nicotinamide-expanded UCB and 21 days (95% CI, 20 to 23 days) for the comparator ( P < .001). The median time to platelet recovery was 34 days (95% CI, 32 to 42 days) and 46 days (95% CI, 42 to 50 days) for the expanded and the comparator cohorts, respectively ( P < .001). The cumulative incidence of grade 2 to 4 acute graft-versus-host disease (GVHD) at day 100 was 44%, and grade 3 and 4 acute GVHD at day 100 was 11%. The cumulative incidence at 2 years of all chronic GVHD was 40%, and moderate/severe chronic GVHD was 10%. The 2-year cumulative incidences of nonrelapse mortality and relapse were 24% and 33%, respectively. The 2-year probabilities of overall and disease-free survival were 51% and 43%, respectively. UCB expanded ex vivo with nicotinamide shortens median neutrophil recovery by 9.5 days (95% CI, 7 to 12 days) and median platelet recovery by 12 days (95% CI, 3 to 16.5 days). This trial establishes feasibility, safety, and efficacy of an ex vivo expanded UCB unit as a stand-alone graft.
Identifiants
pubmed: 30523748
doi: 10.1200/JCO.18.00053
pmc: PMC6368416
doi:
Substances chimiques
Niacinamide
25X51I8RD4
Banques de données
ClinicalTrials.gov
['NCT01816230']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
367-374Subventions
Organisme : NCI NIH HHS
ID : P30 CA077598
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Exp Hematol. 2012 Apr;40(4):342-55.e1
pubmed: 22198152
Biol Blood Marrow Transplant. 2016 Feb;22(2):359-370
pubmed: 26409243
Blood. 2005 Feb 1;105(3):1343-7
pubmed: 15466923
Science. 2014 Sep 19;345(6203):1509-12
pubmed: 25237102
J Clin Invest. 2014 Jul;124(7):3121-8
pubmed: 24911148
Cell Stem Cell. 2016 Jan 7;18(1):144-55
pubmed: 26669897
N Engl J Med. 2012 Dec 13;367(24):2305-15
pubmed: 23234514
Nat Med. 2010 Feb;16(2):232-6
pubmed: 20081862
Br J Haematol. 2015 Feb;168(3):405-12
pubmed: 25272241
Lancet Oncol. 2010 Jul;11(7):653-60
pubmed: 20558104
Biol Blood Marrow Transplant. 2017 Jul;23(7):1151-1157
pubmed: 28392378
N Engl J Med. 2012 Oct 18;367(16):1487-96
pubmed: 23075175
Ther Drug Monit. 2012 Oct;34(5):574-83
pubmed: 22972539
Biol Blood Marrow Transplant. 2018 Jul;24(7):1463-1470
pubmed: 29477778
Biol Blood Marrow Transplant. 2017 Nov;23(11):1949-1954
pubmed: 28729147
Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307
pubmed: 25797174
Blood. 2016 Mar 17;127(11):1502-8
pubmed: 26764356
Blood. 2012 Jul 26;120(4):905-13
pubmed: 22709687
N Engl J Med. 2014 Oct 30;371(18):1685-94
pubmed: 25354103